What is Sitryx?
Sitryx is a UK-based biopharmaceutical company dedicated to developing novel therapeutics by targeting cell metabolism. The company's scientific foundation is built upon the expertise of its world-class academic founders, who have made significant breakthroughs in understanding the energetic status of immune cells and its impact on immunology. Sitryx's pipeline includes drug discovery projects at various stages, aiming to address unmet needs in immuno-inflammation and immuno-oncology.
How much funding has Sitryx raised?
Sitryx has raised a total of $69M across 2 funding rounds:
Series A
$30M
Other Financing Round
$39M
Series A (2018): $30M, investors not publicly disclosed
Other Financing Round (2023): $39M led by Oxford Sciences Enterprises, Sofinnova Partners, and Eli Lilly
Key Investors in Sitryx
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent investment company with a strong partnership with the University of Oxford, focusing on building transformational businesses.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, actively building companies across the entire value chain from seed to later-stage.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical firm focused on the discovery, development, and commercialization of prescription medicines across various therapeutic areas.
What's next for Sitryx?
With a recent major strategic investment and a substantial total funding amount, Sitryx is well-positioned for its next phase of growth. The company's focus on a critical area of biology, coupled with its experienced leadership and strong academic backing, suggests a trajectory towards advancing its drug discovery programs. Future developments will likely involve further pipeline progression and potential strategic collaborations to bring its innovative therapies to market.
See full Sitryx company page
